Johnson & Johnson's manufacturing partner Emergent BioSolutions said on Thursday that it had disposed of a single batch of COVID-19 drug substance that did not meet specifications, a day after J&J said it had found a problem with a batch being produced at Emergent's site in Baltimore, Maryland. Colette Luke has more.br br Johnson & Johnson's manufacturing partner Emergent BioSolutions said on Thursday that it had disposed of the single batch of COVID-19 drug substance that did not meet specifications.br br This comes after J&J said on Wednesday that it had found a problem with a batch of the drug substance for its COVID-19 vaccine being produced at Emergent's site in Baltimore, Maryland, adding that the batch did not advance to the final fill-and-finish stage.